Common Triggers and Causes of Telogen Effluvium

Telogen effluvium can follow many different forms of physiological stress. Commonly recognized triggers include significant illness, high fever, major surgery, severe infection, childbirth, substantial blood loss, rapid weight loss, major dietary restriction and significant changes in nutrition or metabolism.

Postpartum shedding is a classic example. During pregnancy, hormonal changes keep a greater proportion of follicles in the growth phase. After delivery, many of those follicles transition toward telogen within a relatively short period, producing noticeable shedding several months later. In most women, the hair cycle gradually returns toward its previous pattern.

Thyroid disease and other endocrine or metabolic disorders can also produce diffuse shedding. Changes in sex hormones, including starting, stopping or changing certain hormonal therapies or contraceptives, may alter hair cycling in susceptible individuals.

Major illness can trigger TE even after a person appears to have recovered. This delayed relationship can make the cause difficult to recognize because the shedding may begin months after the original illness, fever, hospitalization or surgery.

Psychological stress is frequently blamed for TE. Significant or prolonged emotional stress may contribute to altered hair cycling in some people, but stress should not automatically be assumed to explain otherwise unexplained shedding. Medical, nutritional, hormonal and medication related causes should also be considered.

Weight Loss, GLP 1 Receptor Agonists and Hair Shedding

Rapid or substantial weight loss is a well recognized trigger for telogen effluvium. Severe calorie restriction, inadequate protein intake, bariatric surgery, illness and other major metabolic changes can all disrupt normal hair cycling.

Hair shedding has also been increasingly reported in people using GLP 1 receptor agonist medications, including semaglutide and tirzepatide. The relationship is likely complex. Rapid weight reduction, reduced calorie or protein intake, nutritional changes and the physiological stress of substantial weight loss may all contribute.

It has not been established that these medications directly damage hair follicles. A medication related biological effect has not been completely excluded, but current evidence does not justify assuming that every episode of hair loss occurring during GLP 1 treatment is caused directly by the drug itself.

Weight loss associated shedding can also expose previously subtle androgenetic alopecia. A person may recover from the telogen effluvium yet remain thinner than before because an underlying pattern hair loss process was already developing.

Nutritional Factors and Telogen Effluvium

Inadequate calorie or protein intake can interfere with normal hair growth, particularly when dietary restriction is substantial or prolonged.

Iron deficiency is another important consideration. Hair shedding can occur in people with depleted iron stores even when obvious anemia is not present, although the relationship between iron status and hair loss is complex. There is no single ferritin value that universally proves or excludes iron related shedding in every patient, and laboratory results should be interpreted together with the medical history and clinical findings.

Deficiencies involving vitamin B12, vitamin D, zinc and other nutrients may be relevant in selected individuals, particularly when dietary history, medical illness or laboratory findings suggest a deficiency. Routine supplementation of every nutrient associated with hair growth is not an evidence based treatment for TE.

More is not necessarily better. Excessive intake of certain nutrients, including vitamin A and selenium, can itself contribute to hair loss.

The goal should be to identify and correct a genuine deficiency rather than treating unexplained shedding with increasingly large combinations of vitamins and supplements.

Medication Related Telogen Effluvium

Many medications can alter the normal hair cycle and contribute to diffuse shedding. Reported examples include retinoids, anticoagulants, beta blockers, anticonvulsants, some psychiatric medications and hormonal therapies, among others.

The timing can make medication related hair loss difficult to recognize. Shedding may not begin until weeks or months after a medication is started, discontinued or its dose is changed.

Medication exposure should therefore be included in a careful hair loss history, including prescription medications, over the counter drugs, supplements and recent hormonal changes.

A medication should not be stopped solely because hair shedding develops without first discussing the situation with the prescribing physician. The consequences of stopping a necessary medication can be considerably more serious than the hair loss itself, and another cause of the shedding may ultimately be identified.

Trichodynia and Scalp Symptoms

Some people experiencing diffuse shedding also report scalp tenderness, burning, discomfort, tingling or pain. These symptoms are sometimes collectively described as trichodynia.

Trichodynia can occur in association with telogen effluvium and androgenetic alopecia, but it is not specific to either condition and does not by itself establish a diagnosis or prove that follicles are being permanently damaged.

Persistent redness, heavy scaling, pustules, crusting or focal areas of significant pain should prompt consideration of other scalp disorders, including inflammatory, infectious and scarring conditions.

Diagnosis and Treatment of Telogen Effluvium

The most important step in managing telogen effluvium is identifying and, when possible, correcting the underlying trigger. Diagnosis begins with a careful history that looks back several months before the onset of shedding because the responsible event may have occurred well before the hair loss became noticeable.

The timing of illness, surgery, childbirth, weight changes, dietary changes, medication exposure, hormonal changes and other major events can provide critical clues.

Examination of the scalp and hair, a hair pull test and trichoscopy can help evaluate diffuse shedding and distinguish TE from other forms of hair loss. Standardized washing or hair collection methods and serial photographs may also be useful in selected patients.

Traditional rules stating that a specific number of hairs shed each day automatically represents abnormal hair loss should be interpreted cautiously. The amount of hair a person notices is affected by baseline density, hair length, washing frequency, brushing and grooming habits. A person who washes long hair every several days may see a dramatic collection of shed hairs without actually losing more hair each day than someone who washes daily.

The differential diagnosis can include androgenetic alopecia, diffuse alopecia areata, alopecia areata incognita, hair shaft breakage and other causes of diffuse thinning. More than one condition may be present at the same time.

Laboratory testing should be directed by the medical history and clinical findings rather than automatically ordering every test associated with hair loss. A complete blood count, ferritin and other iron studies, thyroid testing and selected nutritional studies may be appropriate when deficiency or systemic disease is suspected.

A scalp biopsy is rarely required for straightforward acute TE but can be valuable when the diagnosis remains unclear or another disorder is suspected.

Treatment of acute TE primarily involves identifying and correcting the precipitating factor while allowing the hair cycle to recover. There is no medication that is required for every case of uncomplicated acute telogen effluvium.

Minoxidil is sometimes considered when shedding is persistent or androgenetic alopecia is also present. Topical minoxidil is much better established for pattern hair loss than for uncomplicated acute TE, although emerging evidence suggests that it may have a role in selected patients with persistent shedding.

Low dose oral minoxidil is also used off label by some physicians for chronic shedding and overlapping androgenetic alopecia. Evidence specifically for isolated telogen effluvium remains limited. Potential systemic adverse effects, including unwanted body or facial hair growth, fluid retention and cardiovascular effects, need to be considered and discussed with the treating physician.

Minoxidil itself can temporarily increase shedding when treatment is first started because follicles are being shifted into a new growth cycle. That initial shedding should not automatically be interpreted as worsening of the underlying disease.

Recovery and Regrowth After Telogen Effluvium

Acute telogen effluvium frequently improves after the triggering event has resolved, but recovery does not occur overnight.

The first noticeable change is often a reduction in excessive shedding. Visible density recovers more slowly because newly growing hairs must become long enough and thick enough to contribute to scalp coverage.

Short regrowing hairs may become visible over subsequent months. Depending on hair length, the severity of the episode and whether another hair disorder is present, cosmetic recovery can take many months and sometimes considerably longer than the active shedding episode itself.

A person may not return completely to the density remembered before the episode if TE has exposed previously subtle androgenetic alopecia or if another process is occurring at the same time.

This is why persistent thinning after the shedding has improved deserves reassessment rather than automatically being attributed to slow TE recovery.

Anagen Effluvium

Anagen effluvium is a rapid form of nonscarring hair loss caused by interruption or injury to hairs during the active growth phase. The rapidly dividing cells responsible for producing the hair shaft are particularly vulnerable to medications, radiation, toxins and other insults that interfere with cellular division.

Chemotherapy is the best known cause of anagen effluvium. Depending on the medication, dose and treatment regimen, hair loss may begin within approximately two to three weeks after treatment starts and can progress rapidly. Scalp hair is usually most visibly affected, but eyebrows, eyelashes and other body hair may also be lost.

Radiation directed at the scalp can also disrupt actively growing follicles. Whether hair loss is temporary or permanent depends in part on the radiation dose and the degree of follicular injury.

Unlike telogen effluvium, affected follicles in anagen effluvium do not first complete the normal transition into telogen before the hair is lost. Instead, active hair production is abruptly disrupted, weakening or narrowing the growing hair shaft until it fractures or is shed.

Examination of affected hairs and trichoscopy may reveal abnormal growing hairs known as dystrophic anagen hairs.

Certain toxic exposures and medications can also produce anagen effluvium, although chemotherapy induced hair loss remains the most familiar clinical example.

In many cases of chemotherapy induced anagen effluvium, the structures responsible for future hair growth remain capable of recovery and hair begins growing again after treatment has ended. New hair may initially return with a different texture, curl pattern, thickness or color.

Persistent Chemotherapy Induced Alopecia

Chemotherapy related hair loss should not be described as universally reversible.

A minority of patients experience incomplete or substantially reduced regrowth that persists after chemotherapy has ended. Persistent chemotherapy induced alopecia is generally used to describe absent or incomplete recovery extending beyond the period in which normal regrowth would ordinarily be expected, often beyond six months.

Certain chemotherapy agents and treatment regimens appear more strongly associated with persistent alopecia than others, including some taxane based regimens and high dose busulfan containing treatment.

The resulting pattern can sometimes resemble androgenetic alopecia, particularly when the central scalp remains thin after other areas recover.

Patients who experience poor regrowth after chemotherapy should therefore be evaluated rather than simply being told to continue waiting indefinitely. Other contributors, including endocrine therapy, nutritional changes, androgenetic alopecia and additional medical factors, may also influence recovery.

Scalp Cooling and Chemotherapy Induced Hair Loss

Scalp cooling is an established option for reducing chemotherapy induced hair loss in appropriately selected patients.

The scalp is cooled before, during and after chemotherapy. Lower temperature reduces blood flow to the scalp and decreases metabolic activity within the follicles, which can reduce their exposure and susceptibility to certain chemotherapy drugs.

FDA cleared automated scalp cooling systems are available in the United States for selected patients receiving chemotherapy for solid tumors.

Effectiveness varies according to the chemotherapy regimen, drug dose and individual patient factors. Scalp cooling can substantially reduce hair loss for some patients but does not prevent alopecia in everyone.

Cold discomfort and headache are among the most frequently reported adverse effects. Appropriate patient selection remains important because scalp cooling is not suitable for every cancer, treatment regimen or clinical situation.

Concern has historically been raised that reducing chemotherapy exposure to the scalp might increase the risk of cancer later appearing there. Available clinical evidence has not demonstrated an unacceptable increase in scalp metastases among appropriately selected patients, but the decision to use scalp cooling should be made with the treating oncology team.

When Ongoing Shedding Needs Further Evaluation

Hair shedding naturally fluctuates, and a temporary increase does not always indicate disease. Persistent, dramatic or unexplained shedding deserves more careful evaluation, particularly when visible density continues to decline.

Evaluation becomes especially important when diffuse shedding is accompanied by progressive patterned thinning, patchy loss, eyebrow or eyelash loss, scalp redness, scaling, pustules, pain, scarring or other changes that are not typical of uncomplicated telogen effluvium.

The central question is not simply whether someone is shedding hair. It is why the hair cycle has changed and whether another hair loss disorder is occurring at the same time.

Identifying that distinction is essential because telogen effluvium, androgenetic alopecia, alopecia areata and inflammatory or scarring disorders require very different approaches to diagnosis, treatment and long term management.